2 October 2024
Physiomics plc
("Physiomics" or the "Company")
New Services Launch and Website
Update
Physiomics plc (AIM: PYC), a leading
mathematical modelling and data science company supporting the
development of new therapeutics and personalised medicine
solutions, is pleased to announce the official launch of its
Biostatistics offering and expansion of its Data Science and
Bioinformatics services.
Leveraging its existing expertise and
capabilities across the core Modelling and Simulation service line,
the Company is moving forward to expand its offering into the
synergistic service areas of Biostatistics and Data Science; both
of which play crucial roles in drug development.
Biostatistics:
Biostatistics is an essential component of
clinical research. It plays a pivotal role in the setup, conduct
and reporting of all trials, regardless of therapeutic area,
ensuring studies are well designed, data is accurately collected
and analysed, and the results are interpreted correctly.
For example, during the design of interventional trials,
biostatistics is used to calculate the optimum number of patients
to be recruited and help define what data should be collected so
that the effect of the therapy can be detected, balancing this
against the size and cost of the trial.
The strategic rationale for Physiomics to
develop the new Biostatistics services is three-fold. Firstly, the
application of Modelling & Simulation and Biostatistics in drug
development overlaps, with often the output of the former being a
key input to the latter, allowing for natural follow-on work to be
offered to clients. Secondly, biostatistics is a necessary
component to the setup, conduct and reporting of any interventional
clinical trial, from Phase 1 through to Phase 4, regardless of the
therapeutic area. This opens a significant market for the Company,
giving greater opportunity to scale. Finally, with both service
lines utilising the same business model and similar expertise
across mathematics and data science, this allows the Company to
operate flexible staffing across service lines to meet demand and
maximise utilisation.
Data Science
and Bioinformatics:
Data Science and Bioinformatics have also become
critical capabilities across the drug development continuum. From
discovery through into the clinic, the volume and complexity of
data being generated is increasing significantly, driven in part by
advancements in technologies and regulatory pressures. Being able
to effectively make use of this often-disparate data and derive
insights from it is often where the challenge lies for drug
developers. Data science and Bioinformatics tools and methodologies
allow for the effective selection, curation, analysis and
visualisation of this data.
The Company has already been leveraging Data
Science and Bioinformatics tools and methodologies as part of its
core Modelling and Simulation service line, selecting and curating
data required to develop and calibrate its models. The opportunity
to use these tools and models outside Modelling and Simulation has
become more apparent, with the Company delivering on its first pure
Data Science and Bioinformatics project earlier in the year. During
this project, the Company supported the client capture and curated
a wide range of publicly available data relating to novel oncology
drug targets. The data was processed and then presented in a form
that allowed the client to determine the optimum drug target across
a variety of tissue types. Physiomics is keen to build upon this
success and identify new opportunities in this space.
Launch:
As of 30 September 2024, Physiomics has
officially launched its new Biostatistics offering, as well as its
expanded offering in Data Science and Bioinformatics, allowing the
Company to offer a more integrated offering to its clients. To
coincide with this, the Company has completed an update of its
website (www.physiomics.co.uk) and
marketing materials to support a variety of go-to-market activities
and campaigns over the coming weeks.
Dr Peter
Sargent, CEO, commented: "We are delighted to have launched the new
Biostatistics service line, as well as expand our Data Science and
Bioinformatics Services. Not only can we now provide our clients a
great breadth of services to support their drug development
efforts, but these new services are an important component of the
Company's growth strategy."
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines cutting edge
PKPD and QSP modelling and data science techniques, along with deep
biology expertise, to help biotech and pharma companies streamline
their drug development journeys.
Our approach is to derive insight
from all relevant data in order to de-risk decision making and
optimise design research across discovery, pre-clinical and
clinical studies.
Through use of bespoke models and
our proprietary Virtual Tumour technology, the Physiomics team has
informed the development of over 100 commercial projects, over 50
targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.
